Radiation therapy technology company Accuray has entered into agreements with Samsung NeuroLogica to pursue advanced volumetric imaging capabilities for its CyberKnife robotic radiosurgery platform.
The announcement, which coincided with the American Society of Radiation Oncology (ASTRO) Annual Meeting in Boston, brings together Samsung NeuroLogica’s experience in mobile computed tomography (CT) with Accuray’s expertise in precision treatment delivery, robotic radiosurgery and motion management.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to Accuray, the initiative is driven by consistent clinician feedback identifying imaging capabilities that enhance treatment efficiency and support informed decision-making as key priorities. Volumetric imaging is regarded as a way to bring additional imaging information closer to treatment decision-making, potentially improving anatomical visualisation during procedures.
Accuray president and CEO Steve La Neve said: “When I joined Accuray, I spoke about the importance of bringing meaningful innovation to customers with greater focus and speed.
“That requires clarity about where Accuray should lead, where we should collaborate, and how we translate customer priorities into action. Our collaboration with Samsung NeuroLogica reflects that approach by bringing together complementary expertise to pursue opportunities that are expected to help address important customer and patient needs.”
The collaboration remains at an early stage. Development will proceed in phases as the two companies evaluate technical, clinical and commercial viability, and no commercial product has been announced.
Any future outcomes will be subject to ongoing assessment and applicable regulatory requirements.
Samsung HME America mobile CT business head Boris Geyzer said: “Our team has spent years developing mobile CT, bringing imaging to the patient. The discussion with Accuray begins with a practical clinical need: better visualisation of anatomy in the treatment room.
“Samsung NeuroLogica brings deep experience in mobile computed tomography, while Accuray brings precision treatment-delivery expertise and a close understanding of radiotherapy workflows. By bringing these perspectives together, we believe that we can facilitate use of volumetric imaging to address meaningful needs in the treatment room.”
The Samsung NeuroLogica arrangement forms part of Accuray’s wider strategy of combining internally developed technologies with targeted external partnerships to accelerate product development.
Earlier this month, the company and RaySearch Laboratories announced a definitive agreement for an expanded collaboration aimed at expediting Accuray’s adoption of online adaptive radiation therapy. That effort, which pairs Accuray’s photon-based treatment platforms with RaySearch’s planning and workflow software, will initially focus on the Radixact system before extending to CyberKnife.
